ArticleTranslational psychiatry2017
BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology.
Article in Translational psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 51 citations in OpenAlex.
- Multi-Target Inhibitor of ZJQ- 3 F Against AChE/BACE1/GSK3β Targets Improves the Cognitive Impairment of APP/PS1/Tau Triple-Transgenic Mouse Models of Alzheimer's Disease.Molecular neurobiology · 2025Article
- Lithium and neuroprotection: a review of molecular targets and biological effects at subtherapeutic concentrations in preclinical models of Alzheimer's disease.International journal of bipolar disorders · 2025Review
- An Overview of the Effects of Lithium on Alzheimer's Disease: A Historical Perspective.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Trace Lithium for Suicide Prevention and Dementia Prevention: A Qualitative Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Examination of Akt and GSK3β in BDNF-mediated reductions in BACE1 activity in neuronal cells.Physiological reports · 2024Article
- Early oxidative stress and DNA damage in Aβ-burdened hippocampal neurons in an Alzheimer's-like transgenic rat model.Communications biology · 2024Article
- Lithium and its effects: does dose matter?International journal of bipolar disorders · 2024Review
- How close is autophagy-targeting therapy for Alzheimer's disease to clinical use? A summary of autophagy modulators in clinical studies.Frontiers in cell and developmental biology · 2024Review
- Molecular mechanisms and therapeutic potential of lithium in Alzheimer's disease: repurposing an old class of drugs.Frontiers in pharmacology · 2024Review
- Drug Discovery and Development Targeting Dementia.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Beyond its Psychiatric Use: The Benefits of Low-dose Lithium Supplementation.Current neuropharmacology · 2023Review
- Nicotinamide as potential biomarker for Alzheimer's disease: A translational study based on metabolomics.Frontiers in molecular biosciences · 2022Article
- Potent and Selective Inhibitors of Human Monoamine Oxidase A from an Endogenous Lichen FungusJournal of fungi (Basel, Switzerland) · 2021Article
- Chromenone Derivatives as Monoamine Oxidase Inhibitors from Marine-Derived MAR4 CladeJournal of microbiology and biotechnology · 2021Article
- Translational evidence for lithium-induced brain plasticity and neuroprotection in the treatment of neuropsychiatric disorders.Translational psychiatry · 2021Review
- The β-Secretase BACE1 in Alzheimer's Disease.Biological psychiatry · 2021Review
- Repurposing Licensed Drugs for Use Against Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2021Review
- Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer's Disease, Lithium, and Autophagy.International journal of molecular sciences · 2020Review
- Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Ted Sourkes, Moussa Youdim and I.Journal of neural transmission (Vienna, Austria : 1996) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Lithium is first-line therapy for bipolar affective disorder and has recently been shown to have protective effects in populations at risk for Alzheimer's disease (AD). However, the mechanism underlying this protection is poorly understood and consequently limits its possible therapeutic application in AD. Moreover, conventional lithium formulations have a narrow therapeutic window and are associated with a severe side effect profile. Here we evaluated a novel microdose formulation of lithium, coded NP03, in a well-characterized rat model of progressive AD-like amyloid pathology. This formulation allows microdose lithium delivery to the brain in the absence of negative side effects. We found that NP03 rescued key initiating components of AD pathology, including inactivating GSK-3β, reducing BACE1 expression and activity, and reducing amyloid levels. Notably, NP03 rescued memory loss, impaired CRTC1 promoter binding of synaptic plasticity genes and hippocampal neurogenesis. These results raise the possibility that NP03 be of therapeutic value in the early or preclinical stages of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.